Search

Together with the public health authorities in the Nordic countries including Åland, the Faroe Islands and Greenland, the authority has gathered knowledge and experience from working with the pandemic. The report will be an important basis for continued updates of pandemic plans and for increased

This report presents an analysis of COVID-19 vaccine effectiveness (VE) after a fourth dose in relation to SARS-CoV-2 infection and severe outcomes due to the omicron variant among persons aged 65 years and older in Sweden.

This report describes the monitoring and surveillance systems for influenza in use during the 2024–2025 winter season and the results of both epidemiological and virological surveillance. Data are also compared to previous influenza seasons. See also the tables and figures section as well as the

This report describes the monitoring systems for influenza in use during the winter season of 2020–2021 and the results of both epidemiological and virological surveillance. Data are also compared to previous influenza seasons.

This report describes epidemiological and virological surveillance results for the influenza season of 2022–2023 in Sweden. Data are also compared to previous influenza seasons.

This report describes epidemiological and virological surveillance results for the 2023-2024 influenza season in Sweden. Data are also compared to previous influenza seasons.

This report describes the monitoring systems for influenza in use during the winter season of 2021–2022 and the results of both epidemiological and virological surveillance. Data are also compared to previous influenza seasons.

This health economic report presents a cost effectiveness analysis of introducing chickenpox vaccination for children in Sweden from a societal and healthcare perspective. It also includes analyses of costs and cost-savings at national and regional levels.

This report presents the health economic analyses informing the recommendation of herpes zoster vaccination for adults with increased risk for disease.